Dongyang Guangyao (06887.HK): Application for clinical trial of the new drug HEC-921 injection targeting LY6G6D/4-1BB dual-specific antibody accepted by the National Medical Products Administration.

Zhitan Finance APP News, Dongyang Pharmaceutical (06887.HK) announced that on June 18, 2026, the China National Medical Products Administration Drug Evaluation Center (Drug Evaluation Center) officially accepted the clinical trial application for the targeted LY6G6D/4-1BB bispecific antibody new drug HEC-921 injection submitted by the group. It is expected that phase I clinical research will officially start in 2026.